Roche

News

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery.

News

Amgen's cancer biosimilars stay on US market as court battle...

Amgen has scored yet another home run in the US courts, this time seeing off a legal challenge from Genentech, which was trying to block it from launching two cut-price cancer biosimilars.

News

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and A

News

NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

News

Mixed results for Roche drugs in prostate cancer and COVID-1...

Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug achieved only one of its targets and its inflammatory

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

Amgen's cancer biosimilars stay on US market as court battle...

FDA approves Pfizer/Merck KGaA's Bavencio in first line blad...

NICE green lights Roche’s Rozlytrek for NTRK tumours

After Celgene deal, BMS shoots up pharma market cap rankings

Mixed results for Roche drugs in prostate cancer and COVID-1...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Roche

Editor's Picks